2026-06-30 · corticosteroids, prednisone, glucocorticoids, weight gain, steroid side effects, iatrogenic Cushing's · 17 min read

How much weight will I gain on prednisone?

About 70 percent of patients on prednisone at 7.5 mg per day or more for 3 months or longer gain weight, with mean gains of 4 to 8 percent of body weight by 6 months (Fardet 2011 Rheumatology). The Wung 2008 American Journal of Medicine giant-cell-arteritis cohort showed the dose-time response clearly: every additional 10 mg per day of prednisone-equivalent adds roughly 1 kg over 6 months. Short bursts of 5 to 14 days for a flare typically cause 1 to 3 kg of mostly fluid-driven gain that resolves within a few weeks of stopping. Long, open-ended courses at higher doses produce the largest and most durable gains, including the central-fat redistribution that defines the iatrogenic Cushing's pattern. The number that matters most is the cumulative dose over months, not the single-day dose.

Is the weight gain just fluid or real fat?

Both, and the mix changes with time. In the first 2 to 4 weeks, fluid retention dominates and adds 1 to 3 kg through mineralocorticoid cross-reactivity (Souverein 2004 Heart; Saag 2024 American College of Rheumatology review). Appetite stimulation begins within days and drives true caloric overconsumption that adds fat over weeks to months (Tataranni 1996 American Journal of Physiology; Udden 2003 Obesity Research). After roughly 3 months of cumulative exposure above 1.5 g prednisone-equivalent, central and visceral fat redistribution becomes the dominant component — moon face, supraclavicular pad, buffalo hump, and abdominal obesity (Fardet 2011 Rheumatology; Newell-Price 2006 Lancet). Fluid resolves quickly with taper. Appetite-driven fat resolves over months. Cushingoid redistribution can take 6 to 12 months to fully reverse after the steroid is stopped.

How long after stopping prednisone will the weight come off?

The fluid component typically resolves within 2 to 4 weeks of taper. The appetite-driven fat gain resolves over 3 to 6 months at the same eating pattern that produced it, because the hyperphagic effect of the drug also reverses. The Cushingoid central redistribution takes the longest — 6 to 12 months of stable, normal-weight baseline behavior to remodel, and a small subset of patients keep some central fat indefinitely. The strongest predictor of full reversal is total cumulative dose and duration: short bursts and tapers under 3 months almost always reverse fully; multi-year maintenance doses can leave a lasting body-composition shift even after the drug is stopped (Fardet 2011 Rheumatology; Strehl 2017 Annals of the Rheumatic Diseases EULAR Glucocorticoid Toxicity Index).

Does inhaled steroid for asthma cause weight gain?

Yes, but very little compared with oral courses. Liu 2013 (Allergy and Asthma Proceedings) and Hubbard 2002 (Thorax) both documented a small but real signal — roughly 0.5 to 1 kg per year at high inhaled doses such as fluticasone 500 micrograms twice daily. Standard maintenance doses contribute essentially nothing measurable. The much bigger issue for asthma patients is oral prednisone bursts: 3 or 4 courses per year of 5 to 14 days each add up to a meaningful cumulative exposure even though no single burst feels like much. Stopping the inhaler to manage weight backfires — undertreated asthma drives more bursts and worse weight outcomes long-term. The right move is to bring the weight concern to your asthma clinician and discuss controller optimization or biologic step-up to reduce burst frequency. See the asthma and weight loss guide for the broader pattern.

Can I take a GLP-1 medication while on prednisone?

It is generally safer and more effective to wait until the disease is stable and the steroid course is closed or down to a low maintenance dose. The GLP-1 trials (Wilding 2021 NEJM STEP-1; Jastreboff 2022 NEJM SURMOUNT-1) excluded patients on active high-dose steroids, so the head-to-head evidence in active flare is thin. Practical reasons to wait: high-dose steroids drive hyperglycemia, fluid retention, and rapid weight change that confounds dose-titration; GLP-1 nausea stacks badly with steroid-induced gastritis; and rapid weight loss during an active autoimmune flare can mask disease activity. Once the taper is complete or stable at a low dose, GLP-1 medications are appropriate for post-steroid regain and are now a routine option discussed at follow-up. Always coordinate with both the prescribing rheumatologist or pulmonologist and the GLP-1 prescriber.

What can I eat to prevent prednisone weight gain?

Four anchors covered by the strongest evidence. First, front-load protein at 1.2 to 1.6 g per kg per day spread across 3 to 4 meals to counter steroid myopathy (Bauer 2013 PROT-AGE; Longland 2016 American Journal of Clinical Nutrition). Second, follow a Mediterranean or DASH eating pattern with sodium under 2,300 mg per day to blunt fluid retention (Whelton 2017 Circulation; Estruch 2018 NEJM PREDIMED). Third, minimize refined carbohydrates and added sugar to reduce the steroid-induced hyperglycemia load (Hwang 2009 Diabetes Care). Fourth, expect appetite stimulation and pre-portion meals and snacks rather than relying on hunger cues, which the drug temporarily disconnects from caloric need (Tataranni 1996 American Journal of Physiology). Restriction below maintenance during an active steroid course is not realistic for most patients — the appetite drive is biological — so the goal is quality and protein adequacy, not aggressive deficit.

Is my moon face from prednisone or Cushing's disease?

If you are taking any form of corticosteroid at a dose that approaches or exceeds physiologic replacement, the answer is almost always the drug, not endogenous Cushing's syndrome. Iatrogenic Cushing's from exogenous steroids is far more common than the endogenous form (Newell-Price 2006 Lancet; Fardet 2011 Rheumatology). The diagnostic test here is a careful drug history — including inhaled, intranasal, topical, and intra-articular forms — not a 24-hour urinary free cortisol, which will be suppressed by the exogenous steroid and is uninformative in this setting. If you are not taking any steroid in any form and have new Cushingoid features, that is the workup that warrants endogenous evaluation. Bring the question to your prescriber. See the Cushing's syndrome and weight gain guide for the endogenous workup.

Why am I gaining weight on a low dose of prednisone?

Three reasons stack. First, what counts as low is dose-and-duration dependent — 5 mg per day for many months produces meaningful cumulative exposure even though the single daily dose feels small (Wung 2008 American Journal of Medicine; Strehl 2017 EULAR Glucocorticoid Toxicity Index). Second, the appetite-stimulating effect appears within days and is roughly dose-proportional but does not require a high dose to drive overeating (Tataranni 1996 American Journal of Physiology). Third, steroid-induced hyperglycemia and the insulin needed to treat it can produce hyperinsulinemia and additional weight gain even at modest steroid doses (Hwang 2009 Diabetes Care; Clore 2009 Endocrine Practice). The honest framing is that there is no truly weight-neutral chronic steroid dose — even 5 mg per day for over 3 months will move weight in most patients. Ask the prescriber whether a steroid-sparing alternative is appropriate.

Corticosteroids and Weight Gain: What Prednisone Does and What Helps

Quick stats

• Weight gain on prednisone ≥7.5 mg/day for ≥3 months: ~70% of patients (Fardet 2011 Rheumatology)
• Mean weight gain at 6 months: 4–8% of body weight
• Steroid-induced diabetes risk at prednisone ≥10 mg/day: ~2× baseline (Hwang 2009 Diabetes Care)
• Inhaled corticosteroids at high dose: ~0.5–1 kg/year (Liu 2013 Allergy Asthma Proc)
• Iatrogenic Cushing’s threshold: ~1.5 g cumulative prednisone-equivalent (Fardet 2011)

The honest picture, in one paragraph

Corticosteroids are unmatched as anti-inflammatory medications, and they are also the single most common iatrogenic cause of meaningful weight gain in adult medicine. Fardet 2011 (Rheumatology) documented weight gain in roughly 70% of patients on prednisone ≥7.5 mg/day for ≥3 months, with mean gain of 4–8% of body weight by 6 months. The Wung 2008 American Journal of Medicine giant-cell-arteritis cohort mapped a clean dose-response: every 10 mg/day increment of prednisone-equivalent adds roughly 1 kg over 6 months. Hwang 2009 (Diabetes Care) and Curtis 2006 (Arthritis & Rheumatism) added the metabolic side — steroid-induced diabetes risk roughly doubles at prednisone-equivalent ≥10 mg/day, and the resulting hyperinsulinemia compounds the weight effect. Liu 2013 (Allergy and Asthma Proceedings) established the inhaled corticosteroid signal as small but real. The Buckley 2017 ACR and Buckley 2024 Endocrine Society glucocorticoid-induced osteoporosis (GIO) guidelines anchor the bone-protection framework, and the Strehl 2017 EULAR Glucocorticoid Toxicity Index frames the cumulative-burden conversation.

What readers actually want to know is what to expect on prednisone vs methylprednisolone vs dexamethasone vs hydrocortisone, how much of the early gain is appetite vs fluid vs true fat, what actually helps during a course (and after the taper), and when iatrogenic Cushing’s features warrant a conversation about taper or steroid-sparing alternatives. The rest of this guide walks through those questions in the order they usually come up.

How corticosteroids are dosed and what counts as “high-dose”

Doses are quoted in prednisone-equivalents so they can be compared across compounds. Replacement dosing for adrenal insufficiency runs around 15–25 mg/day of hydrocortisone (the equivalent of about 5 mg prednisone). Low-dose maintenance for autoimmune disease is typically 5–7.5 mg/day of prednisone. Anything above 7.5 mg/day prednisone-equivalent for more than 3 months is the threshold the Saag 2024 ACR review treats as a meaningful weight, bone, and metabolic exposure.

If you have endogenous Cushingoid features without exogenous steroid exposure, see Cushing’s syndrome and weight gain for the workup. The chronic-stress cortisol picture — elevated endogenous cortisol from non-Cushing’s drivers — is covered in cortisol, stress, and weight gain. For the inhaled-steroid story specifically, see asthma and weight loss and COPD and weight loss.

Why corticosteroids cause weight gain — 4 drivers

The mechanism is not a single pathway. Four drivers stack, and each one peaks at a different point in a course, which is why the weight pattern on chronic steroids is so distinctive.

1. Appetite rises sharply within days of starting

Tataranni 1996 (American Journal of Physiology) and Udden 2003 (Obesity Research) both showed that dexamethasone and prednisone produce a measurable hyperphagic effect within 24–72 hours of starting, mediated by hypothalamic neuropeptide-Y signaling, central leptin resistance, and altered ghrelin dynamics. This is the largest near-term driver and the one patients notice first — a sudden, unfamiliar, almost compulsory hunger that does not respond well to willpower because the satiety signal is biologically blunted. Pre-portioning meals and snacks beats trying to eat by hunger cues during this phase. See mindful eating for weight loss, snacking for weight loss, and high-protein snacks for weight loss for practical templates.

2. Fluid retention adds 1–3 kg in the first 2–4 weeks

Souverein 2004 (Heart) and the Saag 2024 ACR review describe the mineralocorticoid-receptor cross-reactivity that drives sodium and water retention on steroids. Cross-reactivity is highest with hydrocortisone and prednisone and lowest with dexamethasone, which is part of why dexamethasone is chosen in clinical settings where fluid load matters (e.g., brain edema). The fluid component is fully reversible — it resolves within 2–4 weeks of taper — and is also the most diet-responsive: bringing dietary sodium below 2,300 mg/day blunts the rise meaningfully. See blood pressure and weight loss and heart failure and weight loss.

3. Central / visceral fat redistribution emerges after 3+ months

Fardet 2011 (Rheumatology) and Newell-Price 2006 (Lancet) describe the iatrogenic-Cushingoid pattern — moon face, buffalo hump, supraclavicular fat pad, central truncal obesity, and thinning extremities — that emerges at cumulative dose of roughly 1.5 g prednisone-equivalent (about 5 mg/day for 10 months, or 10 mg/day for 5 months). This pattern is partially reversible with taper and time but does not respond to calorie restriction alone; the redistribution is driven by glucocorticoid effects on preadipocyte differentiation and on regional adipose-tissue 11β-HSD1 activity. See Cushing’s syndrome and weight gain and cortisol, stress, and weight gain.

4. Steroid-induced diabetes drives a positive-feedback weight loop

Hwang 2009 (Diabetes Care) and Clore 2009 (Endocrine Practice) document steroid-induced hyperglycemia in 20–40% of patients at prednisone ≥10 mg/day. The clinical sequence is predictable: post-meal glucose rises first, then fasting glucose, and the typical response is added insulin or an oral hypoglycemic agent. Insulin is itself an anabolic hormone, so the treatment for steroid-induced diabetes can compound weight gain through hyperinsulinemia. Pre-existing impaired fasting glucose or type 2 diabetes magnifies the effect. See diabetes and weight loss, insulin resistance and weight loss, and prediabetes and weight loss.

How much each adjustment shifts the trajectory

This is the lookup table to bring to the prescriber. The numbers are average trajectories from the underlying literature, not individual guarantees.

5-step corticosteroid-and-weight protocol

The plan most prescribers will recognize and most patients can actually execute alongside the underlying illness.

Step 1: Confirm dose, form, and expected duration with your prescriber before assuming the weight gain is permanent

Saag 2024 (ACR) is unambiguous: the single biggest variable for weight outcomes is cumulative dose and duration, not the dose on any one day. Ask whether you are on a 5-day flare burst, a 12-week taper, or open-ended maintenance — the answers point to very different planning. A 5-day burst rarely needs anything beyond eating-pattern stability. A 12-week taper needs a protein, sodium, and step-count anchor. Open-ended maintenance needs a real conversation about steroid-sparing alternatives. See cortisol, stress, and weight gain for the broader cortisol framing.

Step 2: Front-load protein at 1.2–1.6 g/kg distributed across 3–4 meals to counter steroid myopathy

Bauer 2013 (PROT-AGE consensus) and Longland 2016 (American Journal of Clinical Nutrition) both support this as the single most evidence-supported behavioral move during a steroid course. Glucocorticoids produce proximal-muscle wasting that emerges within weeks at higher doses, and the resulting loss of lean mass worsens the body-composition picture beyond the scale weight. Protein distribution matters as much as total — 30–40 g per meal across 3–4 eating windows maximizes muscle-protein synthesis. See protein intake for weight loss, preserve muscle during weight loss, and strength training for weight loss.

Step 3: Anchor diet on a Mediterranean / DASH pattern with sodium <2,300 mg/day and minimally refined carbs

Whelton 2017 (Circulation) sets the AHA sodium guidance; Estruch 2018 (NEJM PREDIMED) anchors the Mediterranean pattern’s cardiometabolic benefit. The combination addresses two corticosteroid drivers at once — sodium restriction blunts fluid retention, and the lower glycemic load reduces the steroid-induced hyperglycemia and insulin-driven weight effect. See DASH diet weight loss, Mediterranean diet weight loss, anti-inflammatory diet weight loss, and blood pressure and weight loss.

Step 4: Ask the prescriber about steroid-sparing alternatives if dose is >7.5 mg/day prednisone-equivalent for >3 months

This is the single largest correctable driver of cumulative dose. Saag 2024 (ACR) frames the conversation: methotrexate, azathioprine, hydroxychloroquine, and modern biologics (anti-TNF, anti-IL-6, anti-IL-17, anti-IL-23, JAK inhibitors) all allow meaningful prednisone taper across most rheumatologic, IBD, and dermatologic indications. Lichtenstein 2018 (American Journal of Gastroenterology) anchors the IBD side. The right conversation is not “can I stop my prednisone” but “what is the path to the lowest effective steroid dose given my disease activity.” See lupus and weight loss, rheumatoid arthritis and weight loss, IBD and weight loss, psoriatic arthritis and weight loss, and multiple sclerosis and weight loss.

Step 5: Re-test fasting glucose / HbA1c, blood pressure, and DXA on the schedule your specialty recommends

The Buckley 2017 ACR and Buckley 2024 Endocrine Society GIO guidelines recommend bone-density and metabolic monitoring at 3 months and 12 months on chronic dose for most adults on ≥7.5 mg/day for ≥3 months, with fasting glucose, A1c, and blood pressure layered in per Hwang 2009 (Diabetes Care). For most patients on chronic steroids, this is the minimum testing cadence; high-risk patients (older adults, low baseline bone density, baseline impaired fasting glucose) need more frequent checks. See osteoporosis and weight loss, blood pressure and weight loss, and prediabetes and weight loss.

What treatments actually do — comparison

Special situations

Iatrogenic Cushing’s syndrome and when to think about it

Fardet 2011 (Rheumatology) and Newell-Price 2006 (Lancet) both make the same point: iatrogenic Cushing’s from exogenous corticosteroids is the most common cause of Cushing-pattern features in adults, far more common than endogenous Cushing’s syndrome from pituitary or adrenal disease. The cumulative-dose threshold is roughly 1.5 g of prednisone-equivalent — about 5 mg/day for 10 months, or 10 mg/day for 5 months, or any high-dose course of meaningful duration. The diagnostic test in this setting is not a 24-hour urinary free cortisol or a low-dose dexamethasone suppression test — those will be suppressed by the exogenous steroid and produce uninformative results. The test is a careful drug history, including oral, inhaled, intranasal, topical, intra-articular, and intramuscular forms. If features emerge in a patient with no steroid exposure of any form, then endogenous workup is appropriate. The reversibility picture is the same as for ordinary steroid weight gain — fluid resolves quickly, appetite-driven fat over months, central redistribution over 6–12 months. See Cushing’s syndrome and weight gain for the endogenous workup and cortisol, stress, and weight gain for the chronic-stress cortisol context.

Inhaled and topical corticosteroids — the small-but-real signal

The non-oral routes get a fair amount of patient anxiety but a much smaller weight signal in the data. Liu 2013 (Allergy and Asthma Proceedings) and Hubbard 2002 (Thorax) both documented inhaled corticosteroid weight effects in the range of 0.5–1 kg per year at high maintenance doses — fluticasone 500 µg twice daily or equivalent — and essentially nothing measurable at standard doses. Intra-articular injections produce detectable systemic effects for 2–6 weeks per injection, which is rarely enough cumulative exposure to drive meaningful weight gain unless injections are repeated frequently. Topical dermatologic steroids produce systemic effects only at very high body-surface coverage with high-potency agents under occlusion — most outpatient psoriasis or eczema regimens stay well below the threshold. The practical takeaway: do not stop the inhaled or topical regimen to manage weight. The risk of undertreated asthma, COPD, or inflammatory skin disease is much larger than the small inhaled-steroid weight signal. See asthma and weight loss, COPD and weight loss, psoriasis and weight loss, and rheumatoid arthritis and weight loss.

Adrenal insufficiency and the safe taper

Iliopoulou 2007 (European Journal of Endocrinology) and Joseph 2017 (Endocrinology and Metabolism Clinics of North America) both anchor the same rule: never stop chronic steroids abruptly. Any patient on more than 3 weeks of supraphysiologic corticosteroid is at risk for hypothalamic-pituitary-adrenal (HPA) axis suppression and a potentially life-threatening adrenal crisis if the drug is stopped suddenly or if a stressor (illness, surgery, trauma) is not covered with a stress dose. The taper rate depends on duration and cumulative dose: short courses can be stopped or tapered over 1–2 weeks; multi-year regimens require months of gradual reduction, often with morning ACTH-stimulation testing in selected cases to confirm HPA recovery. Secondary adrenal insufficiency can persist 6–12 months after a long course, which means stress-dose coverage may be needed for surgery or serious illness even after the maintenance dose has stopped. The weight implication: the taper itself often reveals how much of the apparent weight was steroid-driven, as appetite, fluid, and central fat partially normalize. See cortisol, stress, and weight gain and Cushing’s syndrome and weight gain.

Red flags — when to call the prescriber

Most chronic steroid management is uneventful with regular follow-up. The following findings change the picture and warrant a call rather than waiting for the next scheduled visit.

• Sudden 2+ kg weight gain in less than 1 week with shortness of breath or leg swelling — fluid retention vs early cardiac decompensation; same-week call.
• Fasting glucose >180 mg/dL or new polyuria-polydipsia on steroids — steroid-induced diabetes; same-week call (Hwang 2009 Diabetes Care).
• New mood changes, agitation, mania-like symptoms, or insomnia within 1–2 weeks of starting or dose-escalating — steroid psychiatric side effects; same-week call (Brown 2004 Comprehensive Psychiatry).
• New back pain after a fall or even spontaneously on chronic steroids — vertebral compression fracture; urgent imaging (Buckley 2024 Endocrine Society GIO).
• Severe abdominal pain, vomiting, or fever — perforation, severe infection, or adrenal crisis; emergency department.
• Stopping steroids abruptly after more than 3 weeks of use — adrenal-crisis risk; never self-taper; restart the dose and call the prescriber the same day.

Corticosteroids and Weight Gain FAQ

How much weight will I gain on prednisone? About 70% of patients on ≥7.5 mg/day for ≥3 months gain weight, with mean 4–8% of body weight by 6 months (Fardet 2011); every 10 mg/day adds ~1 kg over 6 months (Wung 2008).

Is the weight gain just fluid or real fat? Fluid in the first 2–4 weeks; appetite-driven fat over weeks to months; central redistribution after ~3 months.

How long after stopping prednisone will the weight come off? Fluid in 2–4 weeks; appetite-driven fat in 3–6 months; Cushingoid central fat in 6–12 months.

Does inhaled steroid for asthma cause weight gain? Small but real — ~0.5–1 kg/year at high doses (Liu 2013); standard doses contribute essentially nothing.

Can I take a GLP-1 medication while on prednisone? Generally better to wait until the steroid course is closed or stable at a low dose; coordinate prescribers.

What can I eat to prevent prednisone weight gain? Front-load protein at 1.2–1.6 g/kg, follow a Mediterranean / DASH pattern, sodium <2,300 mg/day, minimize refined carbs.

Is my moon face from prednisone or Cushing’s disease? Almost always the drug if you are on any form of steroid; iatrogenic Cushing’s is far more common than endogenous.

Why am I gaining weight on a low dose of prednisone? Cumulative dose-and-duration matters more than daily dose; appetite stimulation does not require a high dose.